Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC: Heart Failure Position Paper

JACC: Heart Failure

Volumn 8, Issue 5, 2020, Pages 347-358

  Ibrahim, Nasrien E ^a,b   Burnett, John C ^c   Butler, Javed ^d   Camacho, Alexander ^a   Felker, G Michael ^e   Fiuzat, Mona ^e   O'Connor, Christopher ^e,f   Solomon, Scott D ^b,g   Vaduganathan, Muthiah ^b,g   Zile, Michael R ^h   Januzzi, James L ^a,b,i  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f INOVA HEART AND VASCULAR INSTITUTE   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

ⁱ HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

biomarkers; clinical trials; inclusion criteria; natriuretic peptides

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE;

CLINICAL TRIAL (TOPIC); HEART FAILURE; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 85083325336     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2019.12.010     Document Type: Review

References (34)

1. Ibrahim, N.E., Gaggin, H.K., Konstam, M.A., Januzzi, J.L., Established and emerging roles of biomarkers in heart failure clinical trials. Circ Heart Fail, 9, 2016, e002528.
2. Januzzi, J.L., Rehman, S., Mueller, T., van Kimmenade, R.R.J., Lloyd-Jones, D.M., Importance of biomarkers for long-term mortality prediction in acutely dyspneic patients. Clin Chem 56 (2010), 1814–1821.
3. Daubert, M.A., Adams, K., Yow, E., et al. NT-proBNP goal achievement is associated with significant reverse remodeling and improved clinical outcomes in HFrEF. J Am Coll Cardiol HF 7 (2019), 158–168.
4. Kramer, F., Sabbah, H.N., Januzzi, J.J., et al. Redefining the role of biomarkers in heart failure trials: expert consensus document. Heart Fail Rev 22 (2017), 263–277.
5. Aggregate Analysis of ClincalTrials. Available at: https://www.ctti-clinicaltrials.org/aact-database Accessed July 1, 2019.
6. Pitt, B., Pfeffer, M.A., Assmann, S.F., et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370 (2014), 1383–1392.
7. Ponikowski, P., Voors, A.A., Anker, S.D., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37 (2016), 2129–2200.
8. Januzzi, J.L., van Kimmenade, R., Lainchbury, J., et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 27 (2005), 330–337.
9. Januzzi, J.L., Chen-Tournoux, A.A., Christenson, R.H., et al. N-terminal pro–b-type natriuretic peptide in the emergency department: The ICON-RELOADED study. J Am Coll Cardiol 71 (2018), 1191–1200.
10. Savarese, G., Orsini, N., Hage, C., et al. Utilizing NT-proBNP for eligibility and enrichment in trials in HFpEF, HFmrEF, and HFrEF. J Am Coll Cardiol HF 6 (2018), 246–256.
11. Anand Inder, S., Rector Thomas, S., Cleland John, G., et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction. Circ Heart Fail 4 (2011), 569–577.
12. Anand, I.S., Claggett, B., Liu, J., et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. J Am Coll Cardiol HF 5 (2017), 241–252.
13. Mohammed, S.F., Mirzoyev, S.A., Edwards, W.D., et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol HF 2 (2014), 113–122.
14. Takashio, S., Yamamuro, M., Izumiya, Y., et al. Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis. ESC Heart Fail 5 (2018), 27–35.
15. Ibrahim, N.E., Januzzi, J.L., Beyond natriuretic peptides for diagnosis and management of heart failure. Clin Chem 63 (2017), 211–222.
16. Biomarker Guided Discharge of Heart Failure Patients (RADAR). Available at: https://clinicaltrials.gov/ct2/show/NCT03103932 Accessed July 1, 2019.
17. Kristensen, S.L., Jhund, P.S., Mogensen, U.M., et al. Prognostic value of N-terminal pro-B-type natriuretic peptide levels in heart failure patients with and without atrial fibrillation. Circ Heart Fail, 10, 2017, e004409.
18. Myhre, P.L., Vaduganathan, M., Claggett, B.L., et al. Association of natriuretic peptides with cardiovascular prognosis in heart failure with preserved ejection fraction: secondary analysis of the TOPCAT randomized clinical trialassociation of natriuretic peptides with cardiovascular prognosis in heart failure with preserved ejection fractionassociation of natriuretic peptides with cardiovascular prognosis in heart failure with preserved ejection fraction. JAMA Cardiol 3 (2018), 1000–1005.
19. Gupta, D.K., Claggett, B., Wells, Q., et al. Racial differences in circulating natriuretic peptide levels: the atherosclerosis risk in communities study. J Am Heart Assoc, 4, 2015, e001831.
20. McCullough, P.A., Duc, P., Omland, T., et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the breathing not properly multinational study. Am J Kidney Dis 41 (2003), 571–579.
21. Chenevier-Gobeaux, C., Claessens, Y.-E., Voyer, S., Desmoulins, D., Ekindjian, O.G.J.-C., Influence of renal function on N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients admitted for dyspnoea in the emergency department: comparison with brain natriuretic peptide (BNP). Clinica Chimica Acta 361 (2005), 167–175.
22. Madamanchi, C., Alhosaini, H., Sumida, A., Runge, M.S., Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure. Int J Cardiol 176 (2014), 611–617.
23. Wang, T.J., Larson, M.G., Levy, D., et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 90 (2002), 254–258.
24. Vardeny, O., Miller, R., Solomon, S.D., Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. J Am Coll Cardiol HF 2 (2014), 663–670.
25. McMurray, J.J.V., Packer, M., Desai, A.S., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 (2014), 993–1004.
26. Myhre, P.L., Vaduganathan, M., Claggett, B., et al. B-type natriuretic peptide during treatment with sacubitril/valsartan: the PARADIGM-HF Trial. J Am Coll Cardiol 73 (2019), 1264–1272.
27. Zile, M.R., Claggett, B.L., Prescott, M.F., et al. Prognostic implications of changes in N-terminal Pro-B-type natriuretic peptide in patients with heart failure. J Am Coll Cardiol 68 (2016), 2425–2436.
28. Ibrahim, N.E., McCarthy, C.P., Shrestha, S., et al. Effect of neprilysin inhibition on various natriuretic peptide assays. J Am Coll Cardiol 73 (2019), 1273–1284.
29. Pandey, A., Patel, K.V., Vaduganathan, M., et al. Physical activity, fitness, and obesity in heart failure with preserved ejection fraction. J Am Coll Cardiol HF 6 (2018), 975–982.
30. Krauser, D.G., Lloyd-Jones, D.M., Chae, C.U., et al. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. Am Heart J 149 (2005), 744–750.
31. Frankenstein, L., Remppis, A., Nelles, M., et al. Relation of N-terminal pro-brain natriuretic peptide levels and their prognostic power in chronic stable heart failure to obesity status. Eur Heart J 29 (2008), 2634–2640.
32. Stone, G.W., Lindenfeld, J., Abraham, W.T., et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med 379 (2018), 2307–2318.
33. Moss, A.J., Hall, W.J., Cannom, D.S., et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 361 (2009), 1329–1338.
34. Treatment for Heart Failure: Endpoints for Drug Development Guidance for Industry. Available at: https://www.fda.gov/media/128372/download. (Accessed 17 September 2019)